nach oben

Strahlentherapie und Onkologie

Erschienen in:

06.09.2018 | Original Article

Comparison of relative and absolute rectal dose–volume parameters and clinical correlation with acute and late radiation proctitis in prostate cancer patients

verfasst von: Roman Paleny, Michael Bremer, Daniel Walacides, Silke Mainwaring, Kristina Weber, Christoph Henkenberens

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare relative and absolute dose–volume parameters (DV) of the rectum and their clinical correlation with acute and late radiation proctitis (RP) after radiotherapy (RT) for prostate cancer (PCa).

Patients and methods

366 patients received RT for PCa. In total, 49.2% received definitive RT, 20.2% received postoperative RT and 30.6% received salvage RT for biochemical recurrence. In 77.9% of patients, RT was delivered to the prostate or prostate bed, and additional whole pelvic RT was performed in 22.1%. 33.9% received 3D-RT, and 66.1% received IMRT. The median follow-up was 59.5 months (18.0–84.0 months). The relative (in %) and absolute (in ccm) rectal doses from 20–75 Gy including the receiver operating characteristics curves (rAUC) from 30–65 Gy (in % and ccm) and several other clinical parameters were analyzed in univariate and multivariate analyses. We performed the statistical analyses separately for the entire cohort (n = 366), patients with (n = 81) and without (n = 285) pelvic RT, comparing RP vs. RP ≥ grade I.

Results

With the exception of the V50_Gyccm (p = 0.02) in the univariate analyses for acute RP in the entire patient cohort, no absolute DV parameter (in ccm) was statistically significant associated with either acute or late RP. In the multivariate analyses, 3D-RT (p < 0.008) and rAUC_V30–50 _Gy% (p = 0.006) were significant parameters for acute RP for the entire cohort, and the V50_Gy% (p = 0.01) was the significant parameter for patients with pelvic RT. The rAUC_V40–50 _Gy% (p = 0.004) was significant for RT to the prostate/prostate bed. Regarding the statistical analysis for late RP, the rAUC_V30–65 _Gy% (p = 0.001) was significant for the entire cohort, and rAUC_V30–50 _Gy% (p = 0.001) was significant for RT of the prostate/prostate bed. No parameter was significant in patients with pelvic RT.

Conclusion

Absolute DV parameters in ccm are not required for RT in PCa patients.

Wortel RC, Incrocci L, Pos FJ, van der Heide UA, Lebesque JV, Aluwini S et al (2016) Late side effects after image guided intensity modulated radiation therapy compared to 3D-Conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. Int J Radiat Oncol Biol Phys 95:680–689CrossRefPubMed

Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza Rodriguez MA (2015) High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 16:320–327CrossRefPubMed

Waldstein C, Dörr W, Pötter R, Widder J, Goldner G (2017) Postoperative radiotherapy for prostate cancer: morbidity of local-only or local-plus-pelvic radiotherapy. Strahlenther Onkol 194(1):23–30. https://doi.org/10.1007/s00066-017-1215-9 CrossRefPubMedPubMedCentral

Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A et al (2014) Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/UO AP 09/95 trial. Eur Urol 66:243–250CrossRefPubMed

Budäus L, Schiffmann J, Graefen M, Huland H, Tennstedt P, Siegmann A et al (2017) Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy: informing the debate. Strahlenther Onkol 193:692–699CrossRefPubMed

Lohm G, Neumann K, Budach V, Wiegel T, Hoecht T, Gollrad J (2017) Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy: prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression. Strahlenther Onkol 194(4):325–332. https://doi.org/10.1007/s00066-017-1247-1 CrossRefPubMed

Gulliford SL, Foo K, Morgan RC, Aird EG, Bidmead AM, Critchley H et al (2010) Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys 76:747–754CrossRefPubMed

Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A et al (2010) Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 76:10–19CrossRef

Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO (2010) Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 76(3 Suppl):123–129CrossRef

10.

Casares-Magaz O, Muren LP, Moiseenko V, Petersen SE, Pettersson NJ, Høyer M et al (2017) Spatial rectal dose/volume metrics predict patient-reported gastro-intestinal symptoms after radiotherapy for prostate cancer. Acta Oncol 56:1507–1513CrossRefPubMedPubMedCentral

11.

Kupelian PA, Reddy CA, Carlson TP, Wiloughby TR (2002) Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume? Cancer J 8:62–66CrossRefPubMed

12.

D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974CrossRefPubMed

13.

National Cancer Institute (2010) Common terminology criteria for adverse events v4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed 22 Dec 2017

14.

LENT SOMA scales for all anatomic sites. (1995) Int J Radiat Oncol Biol Phys 31:1049–1092.

15.

Fiorino C, Sanguineti G, Cozzarini C, Foppiano F, Piazzolla A, Menegotti L et al (2003) Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 57:953–962CrossRefPubMed

16.

Fiorino C, Fellin G, Rancati T, Vavassori V, Bianchi VC, Borca VC, Girelli G et al (2008) Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys 70:1130–1137CrossRefPubMed

17.

Fiorino C, Cozzarini C, Vavassori V, Sanguineti G, Bianchi C, Cattaneo GM et al (2002) Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol 64:1–12CrossRefPubMed

18.

Someya M, Hori M, Tatoeka K, Nakata K, Takagi M, Saito M et al (2015) Results and DVH analysis of late rectal bleeding in patients treated with 3D-CRT or IMRT for localized prostate cancer. J Radiat Res 56:122–127CrossRefPubMed

19.

Mirjolet C, Walker PM, Gauthier M, Dalban C, Naudy S, Mazoyer F et al (2016) Absolute volume of the rectum and AUC from rectal DVH between 25 and 50 Gy predict acute gastrointestinal toxicity with IG-IMRT in prostate cancer. Radiat Oncol 11:145CrossRefPubMedPubMedCentral

20.

Nuyttens JJ, Milito S, Rust PF, Turrisi AT 3rd (2002) Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer. Radiother Oncol 64:209–214CrossRefPubMed

21.

Huang EH, Pollak A, Levy L, Starkschall G, Dong L, Rosen I et al (2002) Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 54:1314–1321CrossRefPubMed

22.

McDonald AM, Baker CB, Popple RA, Shekar K, Yang ES, Jacob R et al (2014) Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy. Radiat Oncol. https://doi.org/10.1186/1748-717X-9-129 CrossRefPubMedPubMedCentral

23.

Guckenberger M, Andratschke N, Alheit N, Holy R, Moustakis C, Nestle U et al (2014) Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol 190:26–33CrossRefPubMed

24.

Kocher M, Wittig A, Piroth MD, Treuer H, Seegenschmiedt H, Ruge M et al (2014) Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 190:521–531CrossRefPubMed

25.

Shu HK, Lee TT, Vigneauly E, Xia P, Pickett B, Phillips TL et al (2001) Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer. Urology 57:102–107CrossRefPubMed

26.

Chan LW, Xia P, Gottschalk AR, Akazawa M, Scala M, Picket B et al (2008) Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 72:69–77CrossRefPubMed

27.

Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A et al (2008) Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70:1124–1129CrossRefPubMed

28.

Wortel RC, Incrocci L, Pos FJ, Lebesque JV, Witte MG, van der Heide UA et al (2015) Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 91:737–744CrossRefPubMed

29.

Tucker SL, Dong L, Cheung R, Johnson J, Mohan R, Huang EH et al (2004) Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. Int J Radiat Oncol Biol Phys 60:1589–1601CrossRefPubMed

30.

Guckenberger M, Pohl F, Baier K, Meyer J, Koebl O, Flentje M et al (2006) Influence of rectum delineation (rectal volume vs. rectal wall) on IMRT treatment planning of the prostate. Strahlenther Onkol 182:721–726CrossRefPubMed

Titel: Comparison of relative and absolute rectal dose–volume parameters and clinical correlation with acute and late radiation proctitis in prostate cancer patients
verfasst von: Roman Paleny
Michael Bremer
Daniel Walacides
Silke Mainwaring
Kristina Weber
Christoph Henkenberens
Publikationsdatum: 06.09.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 2/2019
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1365-4

Springer Medizin

Comparison of relative and absolute rectal dose–volume parameters and clinical correlation with acute and late radiation proctitis in prostate cancer patients